Benzenesulfonamide Analogs: Synthesis, Anti-GBM Activity and Pharmacoprofiling

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2023 Aug 12

PMID 37569654

Authors

Akshaya Murugesan

Saravanan Konda Mani

Ramesh Thiyagarajan

Suresh Palanivel

Atash V Gurbanov

Fedor I Zubkov

Meenakshisundaram Kandhavelu

Affiliations

Soon will be listed here.

Abstract

The tropomyosin receptor kinase A (TrkA) family of receptor tyrosine kinases (RTKs) emerge as a potential target for glioblastoma (GBM) treatment. Benzenesulfonamide analogs were identified as kinase inhibitors possessing promising anticancer properties. In the present work, four known and two novel benzenesulfonamide derivatives were synthesized, and their inhibitory activities in TrkA overexpressing cells, U87 and MEF cells were investigated. The cytotoxic effect of benzenesulfonamide derivatives and cisplatin was determined using trypan blue exclusion assays. The mode of interaction of benzenesulfonamides with TrkA was predicted by docking and structural analysis. ADMET profiling was also performed for all compounds to calculate the drug likeness property. Appropriate QSAR models were developed for studying structure-activity relationships. Compound 4-[2-(4,4-dimethyl-2,6-dioxocyclohexylidene)hydrazinyl]--(5-methyl-1,3,4-thiadiazol-2-yl)benzenesulfon-amide (AL106) and 4-[2-(1,3-dioxo-1,3-dihydro-2-inden-2-ylidene)hydrazinyl]--(5-methyl-1,3,4-thiadiazol-2-yl)benzenesulfonamide (AL107) showed acceptable binding energies with the active sites for human nerve growth factor receptor, TrkA. Here, AL106 was identified as a potential anti-GBM compound, with an IC value of 58.6 µM with a less toxic effect in non-cancerous cells than the known chemotherapeutic agent, cisplatin. In silico analysis indicated that AL106 formed prominent stabilizing hydrophobic interactions with Tyr359, Ser371, Ile374 and charged interactions with Gln369 of TrkA. Furthermore, in silico analysis of all benzenesulfonamide derivatives revealed that AL106 has good pharmacokinetics properties, drug likeness and toxicity profiles, suggesting the compound may be suitable for clinical trial. Thus, benzenesulfonamide analog, AL106 could potentially induce GBM cell death through its interaction with TrkA and might be an attractive strategy for developing a drug targeted therapy to treat glioblastoma.

References

Nguyen P, Doan P, Rimpilainen T, Konda Mani S, Murugesan A, Yli-Harja O . Synthesis and Preclinical Validation of Novel Indole Derivatives as a GPR17 Agonist for Glioblastoma Treatment. J Med Chem. 2021; 64(15):10908-10918. PMC: 8389915. DOI: 10.1021/acs.jmedchem.1c00277. View

Mutharasu G, Murugesan A, Konda Mani S, Yli-Harja O, Kandhavelu M . Transcriptomic analysis of glioblastoma multiforme providing new insights into GPR17 signaling communication. J Biomol Struct Dyn. 2020; 40(6):2586-2599. DOI: 10.1080/07391102.2020.1841029. View

Hubbard S . Structural analysis of receptor tyrosine kinases. Prog Biophys Mol Biol. 1999; 71(3-4):343-58. DOI: 10.1016/s0079-6107(98)00047-9. View

Gao Y, Huang J . [An extension strategy of Discovery Studio 2.0 for non-bonded interaction energy automatic calculation at the residue level]. Dongwuxue Yanjiu. 2011; 32(3):262-6. DOI: 10.3724/SP.J.1141.2011.03262. View

Hay D, Harris P, Kowalczyk R, Brimble M, Rathbone D, Barwell J . Structure-activity relationships of the N-terminus of calcitonin gene-related peptide: key roles of alanine-5 and threonine-6 in receptor activation. Br J Pharmacol. 2013; 171(2):415-26. PMC: 3904261. DOI: 10.1111/bph.12464. View

Rashid M . Design, synthesis and ADMET prediction of bis-benzimidazole as anticancer agent. Bioorg Chem. 2020; 96:103576. DOI: 10.1016/j.bioorg.2020.103576. View

Goodsell D, Sanner M, Olson A, Forli S . The AutoDock suite at 30. Protein Sci. 2020; 30(1):31-43. PMC: 7737764. DOI: 10.1002/pro.3934. View

Xu G, Abad M, Connolly P, Neeper M, Struble G, Springer B . 4-Amino-6-arylamino-pyrimidine-5-carbaldehyde hydrazones as potent ErbB-2/EGFR dual kinase inhibitors. Bioorg Med Chem Lett. 2008; 18(16):4615-9. DOI: 10.1016/j.bmcl.2008.07.020. View

Stommel J, Kimmelman A, Ying H, Nabioullin R, Ponugoti A, Wiedemeyer R . Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science. 2007; 318(5848):287-90. DOI: 10.1126/science.1142946. View

10.

Doan P, Musa A, Murugesan A, Sipila V, Candeias N, Emmert-Streib F . Glioblastoma Multiforme Stem Cell Cycle Arrest by Alkylaminophenol Through the Modulation of EGFR and CSC Signaling Pathways. Cells. 2020; 9(3). PMC: 7140667. DOI: 10.3390/cells9030681. View

11.

AlSaid M, Al-Mishari A, Soliman A, Ragab F, Ghorab M . Discovery of Benzo[g]quinazolin benzenesulfonamide derivatives as dual EGFR/HER2 inhibitors. Eur J Med Chem. 2017; 141:84-91. DOI: 10.1016/j.ejmech.2017.09.061. View

12.

Abou-Seri S . Synthesis and biological evaluation of novel 2,4'-bis substituted diphenylamines as anticancer agents and potential epidermal growth factor receptor tyrosine kinase inhibitors. Eur J Med Chem. 2010; 45(9):4113-21. DOI: 10.1016/j.ejmech.2010.05.072. View

13.

Blume-Jensen P, Hunter T . Oncogenic kinase signalling. Nature. 2001; 411(6835):355-65. DOI: 10.1038/35077225. View

14.

Giraud S, Loum E, Bessette B, Mathonnet M, Lalloue F . P75 neurotrophin receptor is sequestered in the Golgi apparatus of the U-87 MG human glioblastoma cell line. Int J Oncol. 2010; 38(2):391-9. DOI: 10.3892/ijo.2010.862. View

15.

Geetha T, Seibenhener M, Chen L, Madura K, Wooten M . p62 serves as a shuttling factor for TrkA interaction with the proteasome. Biochem Biophys Res Commun. 2008; 374(1):33-7. PMC: 2561188. DOI: 10.1016/j.bbrc.2008.06.082. View

16.

Gurbanov A, Kuznetsov M, Mahmudov K, Pombeiro A, Resnati G . Resonance Assisted Chalcogen Bonding as a New Synthon in the Design of Dyes. Chemistry. 2020; 26(65):14833-14837. DOI: 10.1002/chem.202002518. View

17.

Descamps S, Toillon R, Adriaenssens E, Pawlowski V, Cool S, Nurcombe V . Nerve growth factor stimulates proliferation and survival of human breast cancer cells through two distinct signaling pathways. J Biol Chem. 2001; 276(21):17864-70. DOI: 10.1074/jbc.M010499200. View

18.

Sun D, Gao W, Hu H, Zhou S . Why 90% of clinical drug development fails and how to improve it?. Acta Pharm Sin B. 2022; 12(7):3049-3062. PMC: 9293739. DOI: 10.1016/j.apsb.2022.02.002. View

19.

Viswanathan A, Kute D, Musa A, Konda Mani S, Sipila V, Emmert-Streib F . 2-(2-(2,4-dioxopentan-3-ylidene)hydrazineyl)benzonitrile as novel inhibitor of receptor tyrosine kinase and PI3K/AKT/mTOR signaling pathway in glioblastoma. Eur J Med Chem. 2019; 166:291-303. DOI: 10.1016/j.ejmech.2019.01.021. View

20.

Verma G, Marella A, Shaquiquzzaman M, Akhtar M, Ali M, Alam M . A review exploring biological activities of hydrazones. J Pharm Bioallied Sci. 2014; 6(2):69-80. PMC: 3983749. DOI: 10.4103/0975-7406.129170. View